GLP-3 RT (10mg)
Specyfikacja techniczna
| Czystość (HPLC) | ≥97% (HPLC) |
| Numer CAS | 2381089-83-2 |
| Forma | White lyophilized powder |
| Przechowywanie | -20°C |
| Sekwencja | Modified triple incretin agonist |
| Masa cząsteczkowa | 4,803.56 g/mol |
| Forma soli | Acetate |
| Rozpuszczalność | Soluble in aqueous buffer |
GLP-3 RT (10mg)
Cena katalogowa w EUR · HU, SK, CZ, PL
- Eurozone (EUR)252,00 EUR
- Węgry (HU)252,00 EUR≈ 100 800 Ft
- Słowacja (SK)252,00 EUR
- Czechy (CZ)252,00 EUR≈ 6 300 Kč
- Polska (PL)252,00 EUR≈ 1071,00 zł
Ta sama cena katalogowa w EUR przy dostawie na Węgry, Słowację, Czechy i Polskę. Płatność w EUR.
Orientacyjne kwoty HUF, CZK i PLN przeliczone z EUR; Słowacja stosuje EUR. Kursy przybliżone. Płatność w EUR.
Retatrutyd — potrójny agonista inkretynowy (GLP-1R, GIPR, GCGR); w centrum uwagi publikacji dotyczących metabolizmu i masy ciała. Przechowywać w temperaturze −20 °C. Wyłącznie RUO — do badań laboratoryjnych; nie do spożycia przez ludzi.
Wyłącznie do badań laboratoryjnych.
Nie do spożycia przez ludzi, zastosowań weterynaryjnych ani diagnostycznych.
From the Peptide Explorer
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Key Mechanisms
- ›GIP receptor agonism
- ›GLP-1 receptor agonism
- ›Glucagon receptor agonism (energy expenditure)
- ›Hepatic lipid metabolism enhancement
- ›Appetite suppression via CNS pathways
Primary Research Areas
- ›Obesity
- ›NASH
- ›Metabolic syndrome
- ›Triple-incretin signaling
- ›Energy expenditure
Key Research Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Overview
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Origin: Triple GIP/GLP-1/glucagon receptor agonist by Eli Lilly
Mechanism of Action
- GIP receptor agonism
- GLP-1 receptor agonism
- Glucagon receptor agonism (energy expenditure)
- Hepatic lipid metabolism enhancement
- Appetite suppression via CNS pathways
Primary Research Areas
- Obesity
- NASH
- Metabolic syndrome
- Triple-incretin signaling
- Energy expenditure
Key Published Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
2-8°C
Important Notice
Retatrutide (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Specyfikacja badawcza
Synthesized for strict analytical consistency. Verified via HPLC/MS.Zobacz standardy jakości →
Przechowywanie i obsługa
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in aqueous buffer
Najczęstsze pytania
What is GLP-3 RT (10mg)?▼
Is GLP-3 RT (10mg) intended for human consumption?▼
How do you verify purity and identity?▼
How should GLP-3 RT (10mg) be stored?▼
Do you provide a Certificate of Analysis (COA)?▼
What purity is GLP-3 RT (10mg)?▼
Verified Research Reviews
Reta is amazing
"really amazing compound and interesting "